Cargando…

Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat

The entry of the coronavirus SARS-CoV-2 into human lung cells can be inhibited by the approved drugs camostat and nafamostat. Here we elucidate the molecular mechanism of these drugs by combining experiments and simulations. In vitro assays confirm that both drugs inhibit the human protein TMPRSS2,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hempel, Tim, Raich, Lluís, Olsson, Simon, Azouz, Nurit P., Klingler, Andrea M., Hoffmann, Markus, Pöhlmann, Stefan, Rothenberg, Marc E., Noé, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Royal Society of Chemistry 2020
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906443/ https://www.ncbi.nlm.nih.gov/pubmed/35382133 http://dx.doi.org/10.1039/d0sc05064d

Ejemplares similares

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
por: Hoffmann, Markus, et al.
Publicado: (2020)

Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2
por: Zhu, Haixia, et al.
Publicado: (2020)

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
por: Hoffmann, Markus, et al.
Publicado: (2021)

Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2
por: Azouz, Nurit P., et al.
Publicado: (2020)

Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2–Priming Protease TMPRSS2
por: Azouz, Nurit P., et al.
Publicado: (2021)

Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach
por: Sonawane, Kailas D., et al.
Publicado: (2021)

Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations
por: Ramakrishnan, Jaganathan, et al.
Publicado: (2021)

Structural modeling and analysis of the SARS-CoV-2 cell entry inhibitor camostat bound to the trypsin-like protease TMPRSS2
por: Escalante, Diego E., et al.
Publicado: (2021)

Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat
por: Sun, Gaohui, et al.
Publicado: (2021)

Inhibition of Listeria Monocytogenes HtrA Protease with Camostat, Gabexate and Nafamostat Mesylates and the Binding Mode of the Inhibitors
por: C, Amrutha M, et al.
Publicado: (2023)

A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells
por: Mahoney, Matthew, et al.
Publicado: (2021)

Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties
por: Hempel, Tim, et al.
Publicado: (2021)

Computational screening of camostat and related compounds against human TMPRSS2: A potential treatment of COVID-19
por: Sharma, Tanuj, et al.
Publicado: (2022)

The Hemagglutinin of Bat-Associated Influenza Viruses Is Activated by TMPRSS2 for pH-Dependent Entry into Bat but Not Human Cells
por: Hoffmann, Markus, et al.
Publicado: (2016)

Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions
por: Weiss, Johanna, et al.
Publicado: (2021)

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
por: Gunst, Jesper D., et al.
Publicado: (2021)

Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
por: Hoffmann, Markus, et al.
Publicado: (2020)

The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19
por: Li, Kun, et al.
Publicado: (2021)

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
por: Hoffmann, Markus, et al.
Publicado: (2020)

Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2
por: Ianevski, Aleksandr, et al.
Publicado: (2021)

RAndomized Clinical Trial Of NAfamostat Mesylate, A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor, in Patients with COVID-19 Pneumonia
por: Seccia, Teresa Maria, et al.
Publicado: (2023)

A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19
por: Kitagawa, Junsaku, et al.
Publicado: (2021)

Camostat mesilate therapy for COVID-19
por: Uno, Yoshiharu
Publicado: (2020)

Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression
por: Gnirß, Kerstin, et al.
Publicado: (2012)

TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection
por: Metzdorf, Kristin, et al.
Publicado: (2023)

Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2
por: Ou, Tianling, et al.
Publicado: (2021)

Nafamostat-Mediated Inhibition of SARS-CoV-2 Ribosomal Frameshifting Is Insufficient to Impair Viral Replication in Vero Cells. Comment on Munshi et al. Identifying Inhibitors of −1 Programmed Ribosomal Frameshifting in a Broad Spectrum of Coronaviruses. Viruses 2022, 14, 177
por: Jäger, Niklas, et al.
Publicado: (2022)

Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture
por: Wettstein, Lukas, et al.
Publicado: (2022)

Crystal structure of nafamostat dimesylate
por: Fujii, Isao
Publicado: (2021)

Nafamostat: Hyperkalaemia: case report
Publicado: (2021)

Protease inhibitor Camostat Mesyalte blocks wild type SARS-CoV-2 and D614G viral entry in human engineered miniature lungs
por: Wu, Tong, et al.
Publicado: (2022)

Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2
por: Qiao, Yuanyuan, et al.
Publicado: (2021)

Molecular docking analysis reveals the functional inhibitory effect of Genistein and Quercetin on TMPRSS2: SARS-COV-2 cell entry facilitator spike protein
por: Manjunathan, Reji, et al.
Publicado: (2022)

Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation
por: Hofmann-Winkler, Heike, et al.
Publicado: (2020)

Native and activated antithrombin inhibits TMPRSS2 activity and SARS‐CoV‐2 infection
por: Wettstein, Lukas, et al.
Publicado: (2022)

Camostat Does Not Inhibit the Proteolytic Activity of Neutrophil Serine Proteases
por: Assylbekova, Akmaral, et al.
Publicado: (2022)

Tmprss2 specific miRNAs as promising regulators for SARS-CoV-2 entry checkpoint
por: Kaur, Taruneet, et al.
Publicado: (2021)

Antiandrogens Target TMPRSS2 and Reduce SARS-CoV-2 Virus Entry in Lung Cells
por: Leach, Damien A, et al.
Publicado: (2021)

NSP16 promotes the expression of TMPRSS2 to enhance SARS-CoV-2 cell entry
por: Han, Tianyu, et al.
Publicado: (2022)

Expression Pattern of the SARS-CoV-2 Entry Genes ACE2 and TMPRSS2 in the Respiratory Tract
por: Liu, Yichuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mvleghmmh2bblcuq5dl4hsfk6b